- Neuroblastoma Research and Treatments
- Ubiquitin and proteasome pathways
- Cancer, Hypoxia, and Metabolism
- Signaling Pathways in Disease
University of Kentucky
2024-2025
Markey Cancer Center
2025
MYCN-amplification is a genetic hallmark of ~40% high-risk neuroblastomas (NBs). Altered glycosylation common feature adult cancer progression, but little known about how signatures such as alter profiles. Herein, matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) revealed increased core fucosylated glycan abundance within neuroblast-rich regions human MYCN-amplified NB tumors. GDP-mannose 4,6-dehydratase (GMDS) responsible for the first-committed and...
<title>Abstract</title> <italic>MYCN-</italic>amplification is a genetic hallmark of ~ 40% high-risk neuroblastomas (NBs). Altered glycosylation common feature adult cancer progression, but little known about how signatures such as <italic>MYCN</italic>-amplification alter profiles. Herein, matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) revealed increased core fucosylated glycan abundance within human <italic>MYCN-</italic>amplified NB tumors. GDP-mannose...